A Safety and Tolerability Study of Jaktinib

Description

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Conditions

Myelofibrosis

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

A Phase 1 Dose Escalation, Safety and Tolerability Study of Jaktinib in Patients With Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) and Who Are Relapsed/ Refractory to a Marketed JAK Inhibitor

A Safety and Tolerability Study of Jaktinib

Condition
Myelofibrosis
Intervention / Treatment

-

Contacts and Locations

Canton

Site 01, Canton, Ohio, United States, 44718

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
  • * Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
  • * At least 18 years of age.
  • * ECOG PS 0, 1, or 2.
  • * Expected life expectancy is greater than 24 weeks.
  • * Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
  • * Major surgery or radiation therapy within 28 days prior to initiation of study drug.
  • * With suspected allergies to jaktinib or its excipient.
  • * Another clinical trial of a new drug or medical instrument within 3 months before screening.
  • * Females who are pregnant, currently breastfeeding, planning to become pregnant.
  • * Unable to adopt effective contraceptive methods during the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Suzhou Zelgen Biopharmaceuticals Co.,Ltd,

Study Record Dates

2025-11-30